Importantly, LPS sensitizes the therapeutic response of both TNBC and ER+ BC to IAP antagonist therapy by inducing the cancer cell apoptosis through toll-like receptor 4 (TLR4) and MyD88 stimulated TNFα production. This evidence concerns the gene MYD88 and cancer.